IP Library › Granted Patent US 8,901,484
Granted Patent B2
US 8,901,484 · App. 13/870,288 · Granted Dec 2, 2014

Quantification of impurities for release testing of peptide products

Inventors: Martin Vogel (Frankfurt am Main, DE); Werner Mueller (Frankfurt am Main, DE)
Assignee: Sanofi-Aventis Deutschland GmbH
H01J49/26G01N33/6848G01N2333/605H01J49/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,901,484
App. No.
13/870,288
Granted
Dec 2, 2014
Kind
B2
Abstract

The present invention relates to a method for the quantitative determination of an impurity present in a peptide product, wherein the impurity cannot be separated from other impurities or the main product. The method particularly involves the use of high resolution mass spectrometry (MS) detection with or without high performance liquid chromatography (HPLC). The method can be used for the investigation of the quality of peptides and proteins, particularly of pharmaceutical peptides and proteins.

Claims (10)

1. A reagent kit for determining the amount of impurities in a Lixisenatide (AVE 0010) product composition, comprising:

(i) at least one stock preparation of Di-Ser(33)-AVE0010 (SEQ ID NO:2) H-G-E-G-T-F-T-S-DL-S-K-Q-M-E-E-E-A-V-R-L-F-I-E-W-L-K-N-G-G-P-S-S-S-G-A-P-P-S-K-K-K-K-K-K-NH 2 and/or

(ii) at least one stock preparation of Di-Ala(35)-AVE0010 (SEQ ID NO:3) H-G-E-G-T-F-T-S-D-L-S-K-Q-M-E-E-E-A-V-R-L-F-I-E-W-L-K-N-G-G-P-S-S-G-A-A-P-P-SK-K-K-K-K-K-NH2.

2. A method for the quality control of a composition comprising an exendin peptide product comprising the amino acid sequence S-S-G-A, comprising quantitatively determining the amount of a Di-Ser(33)-peptide, and/or a Di-Ala(35)-peptide, in said composition.

3. The method of claim 2 , wherein the quantitative determination is carried out according to a method comprising the steps:

(a) providing a composition comprising a peptide product and an unknown amount of at least one impurity, wherein said impurity cannot be separated from the peptide product or another ingredient of the composition by a chromatographic procedure and wherein said impurity co-elutes or substantially co-elutes with the desired peptide product after the chromatographic separation procedure,

(b) providing at least one sample of said composition without said impurity added and at least one further sample of said composition with a known amount of said impurity added,

(c) quantitatively determining said impurity in said sample from step (b) by mass spectrometry, and

(d) calculating the amount of said impurity in said composition based on the results of (c).

4. The method of claim 2 , wherein the composition comprises lixisenatide.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2013
From: VOGEL, MARTIN; MUELLER, WERNER
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 030755/0316 →
Priority Claims (1)
EP PCT/EP2012/057771 · Apr 27, 2012 · regional
Continuity (2)
Provisional Application 61665098 · Jun 27, 2012
Related Publication 20130284912A1 · Oct 31, 2013